A prospective, real-world clinical study of albumin-bound paclitaxel combined with Sindilizumab in the treatment of non-small cell lung cancer

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000039418

Enrollment

Unknown

Registered

2020-10-27

Start date

2020-10-26

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

case series:Immunotherapy combined with chemotherapy or chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with non-small cell lung cancer diagnosed by histopathology or cytology. 2. Clinical (Research) physicians evaluate that patients can benefit from this study. 3. The subjects with normal function of main organs are in accordance with the routine test standard. 4. The subjects voluntarily joined the study, signed informed consent, good compliance, and cooperated with the follow-up.

Exclusion criteria

Exclusion criteria: 1. Patients with known allergic or hypersensitive reaction to the test drug; 2. Pregnant or lactating women; 3. Subjects who participated in other clinical trials within 4 weeks; 4. Patients considered unsuitable by the researchers.

Design outcomes

Primary

Measure	Time frame
PFS;	—

Countries

China

Contacts

Public ContactJiang Ou

The Second People's Hospital of Neijiang

jiangou816@163.com+86 13990570757

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026